Search - tctmd.com

Displaying 1 - 20 of 59

Sort: Relevancy | Date

Presentation TCT 2025

DAPT -Shock-AMI with use of Cangrelor

Presenter: Babar Basir

October 28, 2025

Presentation TCT India 2025

CANGRELOR New kid in anti-platelet therapy: where to prefer & what are its advantages

Presenter: S. Manoj

July 26, 2025

Presentation TCT 2024

TCT 299: Cangrelor Use in Acute Myocardial Infarction Patients Awaiting Coronary Artery Bypass Grafting

Presenter: Jennifer Rymer

October 29, 2024

Presentation TCT 2024

TCT 784: Gender Disparities in Cangrelor Outcomes for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Presenter: Waiel Abusnina

October 29, 2024

Presentation TCT 2024

TCT 174: High Bleeding Risk and Outcomes in Acute Coronary Syndrome After Percutaneous Coronary Intervention With Versus Without Cangrelor

Presenter: Patrick Creechan

October 28, 2024

Presentation TCT 2024

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

Presenter: Angelo Oliva

October 27, 2024

Presentation TCT 2024

TCT 1: Differential Outcomes in ST-Elevation and Non-ST Elevation Myocardial Infarction Outcomes After Percutaneous Coronary Intervention With Versus Without Cangrelor

Presenter: Andrew Hill

October 27, 2024

Presentation TCT 2024

TCT 1351: Cangrelor in a Challenging Scenario of Concomitant Ischemic Stroke, Pulmonary Embolism and STEMI

Presenter: Federico Oliveri

October 27, 2024

Presentation TCT 2024

TCT 238: Safety and Efficacy of Cangrelor: A Multicenter Nationwide Registry ARECA (Austrian Registry for Cangrelor Application)

Presenter: Guy Friedrich

October 27, 2024

Presentation TCT 2024

TCT 236: Bailout Use of Cangrelor During Percutaneous Coronary Intervention and Associated Inpatient Outcomes

Presenter: Abhishek Chaturvedi

October 27, 2024

Presentation TCT 2023

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Presenter: Michael Savage

October 25, 2023

Presentation TCT 2023

Cangrelor Reduces Procedural Complications and Should Be the Default Strategy

Presenter: Jennifer Rymer

October 25, 2023

Presentation TCT 2020

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Presenter: Jennifer Rymer

October 14, 2020

Presentation JIM 2020

Clinical Crossroads On Optimal Antithrombotic Therapy In Patients Treated With Pci Intravenous Antiplatelet Therapy In High Risk Acs

Presenter: Dominick Angiolillo

February 13, 2020

Presentation ARCH 2019

Pharmacology Review of Medications in the Cardiac Cath Lab ARCH 2019

Presenter: Hannah Pope

April 11, 2019

Presentation JIM 2019

Cangrelor is ready for the prime time

Presenter: Giuseppe Musumeci

February 15, 2019

Presentation

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI Patients Undergoing Primary PCI

January 14, 2019

Presentation TCT Abstracts Posters 2018

Cost-Consequence Analysis of Cangrelor Use in High Angiographic Risk Percutaneous Coronary Intervention (PCI) Patients: A US Hospital Perspective

Presenter: Ivar S Jensen

September 25, 2018

Presentation TCT 2018

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Presenter: John A. Bittl, C. Michael Gibson, Deepak L. Bhatt

September 23, 2018

Presentation JIM 2018

Cangrelor is ready for prime time

Presenter: Dominick J. Angiolillo

February 23, 2018

Advertisement

DAPT -Shock-AMI with use of Cangrelor

CANGRELOR New kid in anti-platelet therapy: where to prefer & what are its advantages

TCT 299: Cangrelor Use in Acute Myocardial Infarction Patients Awaiting Coronary Artery Bypass Grafting

TCT 784: Gender Disparities in Cangrelor Outcomes for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

TCT 174: High Bleeding Risk and Outcomes in Acute Coronary Syndrome After Percutaneous Coronary Intervention With Versus Without Cangrelor

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

TCT 1: Differential Outcomes in ST-Elevation and Non-ST Elevation Myocardial Infarction Outcomes After Percutaneous Coronary Intervention With Versus Without Cangrelor

TCT 1351: Cangrelor in a Challenging Scenario of Concomitant Ischemic Stroke, Pulmonary Embolism and STEMI

TCT 238: Safety and Efficacy of Cangrelor: A Multicenter Nationwide Registry ARECA (Austrian Registry for Cangrelor Application)

TCT 236: Bailout Use of Cangrelor During Percutaneous Coronary Intervention and Associated Inpatient Outcomes

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Cangrelor Reduces Procedural Complications and Should Be the Default Strategy

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Clinical Crossroads On Optimal Antithrombotic Therapy In Patients Treated With Pci Intravenous Antiplatelet Therapy In High Risk Acs

Pharmacology Review of Medications in the Cardiac Cath Lab ARCH 2019

Cangrelor is ready for the prime time

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI Patients Undergoing Primary PCI

Cost-Consequence Analysis of Cangrelor Use in High Angiographic Risk Percutaneous Coronary Intervention (PCI) Patients: A US Hospital Perspective

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Cangrelor is ready for prime time

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content